From late 2009 to early 2011, Immunicum conducted in vitro-studies on the CD70-concept with encouraging results. Data  indicated a significantly improved activity and survival of the expanded tumor specific T-cells.

The possibilities to expand both tumor specific and virus specific cytotoxic T-lymphocytes (CTLs) were also evaluated by comparing the CD70-protocol with a protocol that excluded the alloreactive lymphocytes. These studies clearly showed that addition of alloreactive lymphocytes led to a superior expansion of cocultured tumor specific and virus specific (including HIV and influenza) CTLs.

Immunicum’s CD70-concept has been evaluated in a head-to-head comparison with the conventional expansion protocol, Rapid Expansion Protocol (REP), which is used worldwide and is considered “state of the art”. At the end of October 2011, data showed that Immunicum’s concept could expand significantly more CTLs than the REP-protocol. In addition, Immunicum’s expanded T-cells showed significantly improved viability when compared to T-cells expanded with the REP-protocol, and only half as high sensitivity to a drug that kills T-cells.